Skip to content

Buserelin (Acetate)

    Brands

    Buserelin (Acetate)

    DAE Class; Rx

    Common Brand Names; SUPREFACT

    • Ovulation stimulants

    Buserelin (Acetate) is analogue of gonadotrophin-releasing hormone that suppresses androgen production by testes. Buserelin (Acetate) is used in the treatment of carcinoma of prostate and endometriosis.

    Buserelin (Acetate) is primarily indicated in conditions like Endometriosis, Fibroids, In-vitro fertilization programmes, Mobilisation of peripheral blood progenitor cells, Pituitary desensitisation, Polycystic ovary syndrome, Precocious puberty, Prostatic cancer, and can also be given in adjunctive therapy as an alternative drug of choice in Advanced prostate cancer.

    No data regarding the contra indications of Buserelin (Acetate) is available.

    The severe or irreversible adverse effects of Buserelin (Acetate), which give rise to further complications include Histological changes in testis.

    The symptomatic adverse reactions produced by Buserelin (Acetate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Menopausal symptoms, Loss of libido, Hot flushes.

    Buserelin should not generally use in patients with pituitary adenoma. It is also recommended that patients with weight related amenorrhoea should not receive this medication until their weight is corrected. It is not recommended for use during pregnancy.

    Drug should not be given to Pregnant Mothers, and Neonates.

    Drug should not be given to Pregnant Mothers, and Neonates.

    Nasal
    Pituitary desensitisation before ovulation induction with gonadotrophins

    Adult: As 150 mcg/spray preparation: 1 spray in 1 nostril 4 times daily, starting either in the early follicular phase (day 1) or in the mid-luteal phase (day 21, given that the existence of early pregnancy is excluded). Therapy should be continued until pituitary downregulation occurs, which normally takes 2-3 weeks. In some cases, 300 mcg 4 times daily may be given as necessary. Treatment guidelines may vary among countries or individual products. Refer to product-specific recommendations.


    Nasal
    Endometriosis

    Adult: As 150 mcg/spray preparation: 1 spray into each nostril tid (morning, mid-day and evening). Usual treatment duration: 6 months. Treatment guidelines may vary among countries or individual products. Refer to product-specific recommendations.


    Nasal
    Advanced hormone-dependent prostatic carcinoma

    Adult: Maintenance: As 100 mcg/spray preparation: 1 spray into each nostril 6 times daily usually before and after each meal, starting on day 8 (after the 7-day subcutaneous administration). Treatment guidelines may vary among countries or individual products. Refer to product-specific recommendations.


    Subcutaneous
    Pituitary desensitisation before ovulation induction with gonadotrophins

    Adult: Suprecur 200-500 mcg as a single dose daily; a dose of 500 mcg bid may be given as necessary. Suprefact 600 mcg in 3 divided doses daily. Therapy starts either in the early follicular phase (day 1) or in the mid-luteal phase (day 21, given that the existence of early pregnancy is excluded) and continued until pituitary down-regulation occurs, which normally takes 1-3 weeks. Treatment guidelines may vary among countries or individual products. Refer to product-specific recommendations.


    Subcutaneous
    Advanced hormone-dependent prostatic carcinoma

    Adult: 500 mcg 8 hourly for 7 days. Maintenance: Shift to intranasal route on day 8. Treatment guidelines may vary among countries or individual products. Refer to product-specific recommendations.


    Subcutaneous
    Endometriosis

    Adult: 200 mcg daily, starting on the 1st or 2nd day of menstruation; may be increased to 500 mcg as necessary, according to response. Usual treatment duration: 6-9 months. Treatment guidelines may vary among countries or individual products. Refer to product-specific recommendations.

    Buserelin (Acetate)

    Nasal Spray